WuXi AppTec Co., Ltd. (603259.SS)
CNY 56.05
(-0.09%)
CNY 56.05
(-0.09%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 11.87 Billion CNY | 3.01% |
| 2022 | 10.65 Billion CNY | 76.43% |
| 2021 | 6.03 Billion CNY | 78.13% |
| 2020 | 3.38 Billion CNY | 44.79% |
| 2019 | 2.34 Billion CNY | -9.43% |
| 2018 | 2.58 Billion CNY | 76.96% |
| 2017 | 1.46 Billion CNY | 13.7% |
| 2016 | 1.28 Billion CNY | 66.47% |
| 2015 | 771.67 Million CNY | -10.47% |
| 2014 | 861.96 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 2.46 Billion CNY | 6.62% |
| 2024 Q3 | 2.81 Billion CNY | 14.19% |
| 2024 Q1 | 2.3 Billion CNY | -12.56% |
| 2023 FY | 10.97 Billion CNY | 3.01% |
| 2023 Q4 | 2.64 Billion CNY | -22.19% |
| 2023 Q3 | 3.39 Billion CNY | -10.59% |
| 2023 Q1 | 2.61 Billion CNY | -15.49% |
| 2023 Q2 | 3.79 Billion CNY | 45.18% |
| 2022 Q2 | 3.54 Billion CNY | 77.03% |
| 2022 FY | 10.65 Billion CNY | 76.43% |
| 2022 Q4 | 3.09 Billion CNY | 34.92% |
| 2022 Q3 | 2.29 Billion CNY | -35.37% |
| 2022 Q1 | 2 Billion CNY | 15.53% |
| 2021 Q4 | 1.73 Billion CNY | 55.58% |
| 2021 FY | 6.03 Billion CNY | 78.13% |
| 2021 Q3 | 1.11 Billion CNY | -25.1% |
| 2021 Q2 | 1.48 Billion CNY | -12.27% |
| 2021 Q1 | 1.69 Billion CNY | 154.96% |
| 2020 Q2 | 1.51 Billion CNY | 259.56% |
| 2020 Q1 | 420.24 Million CNY | 121.72% |
| 2020 FY | 3.38 Billion CNY | 44.79% |
| 2020 Q4 | 665.79 Million CNY | -15.98% |
| 2020 Q3 | 792.41 Million CNY | -47.56% |
| 2019 Q1 | 506.27 Million CNY | 21.75% |
| 2019 FY | 2.34 Billion CNY | -9.43% |
| 2019 Q4 | 189.54 Million CNY | -78.07% |
| 2019 Q3 | 864.3 Million CNY | 10.7% |
| 2019 Q2 | 780.8 Million CNY | 54.23% |
| 2018 Q3 | 753.5 Million CNY | -28.24% |
| 2018 Q1 | 365.31 Million CNY | 48.29% |
| 2018 Q2 | 1.05 Billion CNY | 187.44% |
| 2018 FY | 2.58 Billion CNY | 76.96% |
| 2018 Q4 | 415.83 Million CNY | -44.81% |
| 2017 Q3 | 353.01 Million CNY | -27.36% |
| 2017 Q1 | 425.12 Million CNY | 0.0% |
| 2017 FY | 1.46 Billion CNY | 13.7% |
| 2017 Q4 | 246.35 Million CNY | -30.21% |
| 2017 Q2 | 485.95 Million CNY | 14.31% |
| 2016 FY | 1.28 Billion CNY | 66.47% |
| 2015 FY | 771.67 Million CNY | -10.47% |
| 2014 FY | 861.96 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 646.8 Million CNY | -1735.532% |
| Joinn Laboratories(China)Co.,Ltd. | 507.09 Million CNY | -2241.229% |
| Autobio Diagnostics Co., Ltd. | 1.36 Billion CNY | -769.288% |
| Thalys Medical Technology Group Inc. | -180.32 Million CNY | 6683.933% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 759.76 Million CNY | -1462.632% |
| Chemclin Diagnostics Co., Ltd. | 166.28 Million CNY | -7039.675% |